Covidien emerged from the ashes of the Tyco International implosion in 2003, spun out of Tyco’s healthcare business. Since then it’s been on a strict diet, shedding non-core or slower-growing businesses and bulking up in areas where it sees opportunity. That’s meant a host of acquisitions aimed at boosting Covidien’s footprint in medical devices, its largest segment (the company also deals in medical supplies and pharmaceuticals). Its commitment to med-tech was also in evidence when it announced plans to spin out its pharmaceuticals unit.
Home » Covidien
More recent news
- Cooper Companies continues to see activist pressure to sell divisions, replace CEO
- Cordis earns FDA nod for Selution SLR drug-eluting balloon
- Siemens Healthineers links with Novo to advance liver fibrosis blood test
- GE HealthCare rolls out AI software for predicting care bottlenecks
- Wandercraft’s self-balancing Eve exoskeleton begins US launch
